Your Ancestry Tells a Story. Your Genes Reveal the Health Risks Hidden Inside It.

APOE encodes apolipoprotein E, a protein that transports cholesterol in your bloodstream and brain. It’s critical for heart health, brain inflammation, and neurological aging. Your APOE status is one of the strongest genetic predictors of cognitive decline in old age.

APOE comes in three common variants: e2, e3, and e4. You inherit one copy from each parent, creating six possible genotype combinations. The e4 allele, carried by roughly 25-30% of people of European ancestry, significantly raises risk for cognitive decline and cardiovascular disease. People with two e4 copies face dramatically elevated Alzheimer’s risk. APOE e4 carriers show accelerated cognitive aging even when other risk factors appear controlled.

If you carry e4, this doesn’t mean you will develop Alzheimer’s. It means your brain is more sensitive to lifestyle factors: sleep quality, cardiovascular fitness, Mediterranean-style diet, cognitive engagement, and inflammation management all become non-negotiable. Your longevity strategy must be more aggressive than it would be for e3/e3 carriers.

MTHFR encodes methylenetetrahydrofolate reductase, an enzyme that converts dietary B vitamins (folate, B12) into their active forms your cells can use. This conversion is essential for creating and repairing DNA, making neurotransmitters, and producing cellular energy. Every cell in your body depends on MTHFR to function.

The C677T variant, carried by roughly 40% of people of European ancestry, reduces enzyme efficiency by 40-70%. The A1298C variant, carried by roughly 30%, reduces it by 20-30%. If you carry two copies of C677T, your cells are struggling to convert B vitamins at roughly one-third normal capacity. You can eat excellent nutrition and still develop a functional B vitamin deficiency because your cells cannot process the B vitamins you consume.

This manifests as unexplained fatigue, brain fog, mood instability, and slow wound healing. You get bloodwork done and everything looks normal because standard testing doesn’t measure methylation capacity. You’re told you’re fine when your cells are actually running on fumes. Methylated B vitamins bypass the broken conversion step entirely.

BRCA1 encodes a tumor suppressor protein that patrols your cells, finds damaged DNA, and repairs it before cancer can develop. Without functional BRCA1, mutations accumulate. Cells start dividing uncontrollably. Cancer develops.

Pathogenic BRCA1 mutations are less common than MTHFR variants, but far more serious. Roughly 1 in 400 to 1 in 800 people of European ancestry carry a deleterious BRCA1 mutation. If you do, your lifetime risk of breast cancer rises to 45-87%, and ovarian cancer risk to 20-44%. For men, prostate cancer risk is elevated. A BRCA1 mutation doesn’t mean you will definitely get cancer, but it means cancer prevention and early detection become medical necessities, not optional.

If you carry a BRCA1 mutation, the entire trajectory of your health changes. Enhanced screening (MRI in addition to mammography), risk-reducing surgery, genetic counseling, and family planning conversations all become relevant. Many people carrying BRCA1 mutations are unaware. Standard screening assumes average risk. You need targeted, aggressive prevention.

F5 encodes clotting factor V, a protein that orchestrates blood clot formation. When you cut yourself, F5 helps your blood coagulate, stopping the bleeding. It’s essential for survival. But too much clotting activity causes strokes, heart attacks, and pulmonary embolism.

The F5 Leiden mutation (rs6025), carried by roughly 5% of people of European ancestry, increases clotting factor V activity. Your blood clots more readily than normal. During surgery, immobility (long flights, bed rest), or pregnancy, this becomes dangerous. People with F5 Leiden have a 3-8 times higher risk of deep vein thrombosis and pulmonary embolism compared to people without the variant. Standard doctors don’t routinely screen for this, which means many people at high risk don’t know it.

If you carry F5 Leiden, pregnancy and surgery change from routine events into situations requiring thrombosis prevention. Birth control pills and hormone replacement therapy increase clot risk further and should be discussed carefully with your doctor. Long flights require compression stockings and movement breaks.

CYP2D6 encodes a liver enzyme that metabolizes roughly 25% of all prescribed medications, including antidepressants, antipsychotics, pain relievers, beta-blockers, and anti-arrhythmics. Your CYP2D6 status determines whether a standard dose is therapeutic, too weak, or toxic for your body.

CYP2D6 comes in dozens of variants. You may be a poor metabolizer (drugs accumulate to toxic levels), intermediate metabolizer (reduced metabolism), normal metabolizer, or ultra-rapid metabolizer (drugs clear too fast to work). Roughly 5-10% of people are poor metabolizers. Roughly 1-5% are ultra-rapid metabolizers. A person with poor CYP2D6 metabolism taking a standard antidepressant dose may experience severe side effects, while an ultra-rapid metabolizer on the same dose gets no benefit at all. Doctors prescribe by population average. Your body has different rules.

If you’ve experienced unusual medication side effects, or if medications haven’t worked despite taking them correctly, CYP2D6 may be the reason. Taking a medication that your body can’t metabolize properly is not a failure of the treatment. It’s a failure to match the treatment to your genetics. Testing determines your status. Dosing can then be personalized.

HLA-DQ2 encodes a human leukocyte antigen (HLA) protein that sits on the surface of your immune cells. It presents antigens (foreign proteins) to your immune system, triggering the decision to attack or tolerate. In people with HLA-DQ2, the immune system misidentifies gluten as a threat. It attacks your small intestine’s lining every time you eat wheat, barley, or rye.

HLA-DQ2 is carried by roughly 30-40% of people of European ancestry, and much higher rates in Southern European and Mediterranean populations. But not everyone with HLA-DQ2 develops celiac disease. Having the gene is necessary but not sufficient. Some people carry it asymptomatically their whole lives. Others develop celiac disease suddenly, triggered by infection, stress, or pregnancy. Carrying HLA-DQ2 means you are at genetic risk for celiac disease, but active disease requires both the gene and immune activation.

If you carry HLA-DQ2 and experience digestive issues, fatigue, anemia, or brain fog, celiac disease should be tested for with tissue serology and small bowel biopsy before eliminating gluten. If you don’t have celiac disease but do carry the gene, periodic screening makes sense because the disease can develop later. If you’re asymptomatic, you don’t need to avoid gluten.